Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.70 |
| ▸ | TK1 | P04183 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | ALB | P02768 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3230623 | 1.00 | RNASE1 (0.70) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL2029315 | 0.91 | RNASE1 (0.65) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL2029313 | 0.91 | RNASE1 (0.65) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL2056647 | 0.89 | RNASE1 (0.69) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL6248265 | 0.88 | RNASE1 (0.68) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL26571124 | 0.88 | RNASE1 (0.68) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL16360133 | 0.88 | RNASE1 (0.68) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL6832175 | 0.87 | RNASE1 (0.67) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL22992460 | 0.86 | RNASE1 (0.69) | RNASE1TK1LMNATSHRALB | |
| SCHEMBL523267 | 0.86 | RNASE1 (0.69) | RNASE1TK1LMNATSHRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846898-B2 | Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotide having reduced internucleotide charge | Lieure Cornu LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100311960-A1 | Phosphinoamidite Carboxylates and Analogs Thereof in the Synthesis of Oligonucleotide Having Reduced Internucleotide Charge | LIEVRE CORNU LLC (US) | 2010-12-09 | — | — | US | disclosed |
| US-7745591-B2 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | Lievre Cornu, LLC (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1334111-A4 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | DELLINGER DOUGLAS J (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20060293511-A1 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | LIEVRE CORNU LLC (US) | 2006-12-28 | — | — | US | disclosed |
| US-7067641-B2 | Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge | LIEVRE CORNU LLC (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040116687-A1 | oligonucleotides having reduced internucleotide charge and enhanced nuclease resistance | AGILENT TECHNOLOGIES, INC. | 2004-06-17 | — | — | US | disclosed |
| US-6693187-B1 | ENHANCING NUCLEASE RESISTANCE | LIEVRE CORNU LLC | 2004-02-17 | — | — | US | disclosed |
| EP-1334111-A2 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | Dellinger, Douglas J. (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002032912-A2 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | DELLINGER DOUGLAS J (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311960-A1 | Phosphinoamidite Carboxylates and Analogs Thereof in the Synthesis of Oligonucleotide Having Reduced Internucleotide Charge | NSUN2, POLL, DUT | RNASE1 325/4885TK1 53/4885LMNA 751/4885 |
| US-20060293511-A1 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | NSUN2, ADAR, POLL | RNASE1 27/4885TK1 206/4885LMNA 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.